Investigation of Serum Sclerostin Levels in Patients With Erectile Dysfunction
Key facts
- Who runs it
- Medipol University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 97 people enrolled
- Started
- 2 Jan 2023
- Ended
- 2 Jan 2024
- Type of study
- Observational, 2 groups
- Record updated
- 28 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Men only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show the criterionShow less
Who cannot take part
- -
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective, observational case-control study aims to investigate the potential role of sclerostin-a molecule associated with cardiovascular pathologies-in the vascular pathogenesis of erectile dysfunction (ED). The study compares peripheral venous sclerostin levels between men diagnosed with ED and healthy volunteers. Additionally, it evaluates cavernosal blood sclerostin levels within the ED group to explore localized vascular changes.
The 2 groups in the trial
- Case Group
Patients diagnosed with erectile dysfunction who undergo the Combined Intracavernosal Injection and Stimulation Test (KİST) and provide peripheral and cavernosal blood samples.
- Control Group
Healthy male volunteers without erectile dysfunction who provide only peripheral venous blood samples.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 28 October 2026